Stock Research for CELG

Current Price


Latest Update: 2018-02-20 16:00:00

$ 93.9500
$ 93.8000
$ 93.8500

Featured Broker: TradeStation

Get the due diligence for another stock.


CELG Stock Chart & Research Data

The CELG chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CELG chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CELG Due diligence Resources & Stock Charts

The CELG stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CELG Detailed Price Forecast - CNN Money CNN View CELG Detailed Summary - Google Finance
Yahoo View CELG Detailed Summary - Yahoo! Finance Zacks View CELG Stock Research & Analysis -

Stock Analysis

TradeIdeas View CELG Trends & Analysis - Trade-Ideas Barrons View CELG Major Holders - Barrons
NASDAQ View CELG Call Transcripts - NASDAQ Seeking View CELG Breaking News & Analysis - Seeking Alpha
Spotlight View CELG Annual Report - OTC Report View CELG OTC Short Report -
TradeKing View CELG Fundamentals - TradeKing Charts View CELG SEC Filings - Bar Chart
WSJ View Historical Prices for CELG - The WSJ Morningstar View Performance/Total Return for CELG - Morningstar
MarketWatch View the Analyst Estimates for CELG - MarketWatch CNBC View the Earnings History for CELG - CNBC
StockMarketWatch View the CELG Earnings - StockMarketWatch MacroAxis View CELG Buy or Sell Recommendations - MacroAxis
Bullish View the CELG Bullish Patterns - American Bulls Short Pains View CELG Short Pain Metrics -

Social Media Mentions

StockTwits View CELG Stock Mentions - StockTwits PennyStocks View CELG Stock Mentions - PennyStockTweets
Twitter View CELG Stock Mentions - Twitter Invest Hub View CELG Investment Forum News - Investor Hub
Yahoo View CELG Stock Mentions - Yahoo! Message Board Seeking Alpha View CELG Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CELG - Insider Cow View Insider Transactions for CELG - Insider Cow
CNBC View CELG Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CELG - OTC Markets
Yahoo View Insider Transactions for CELG - Yahoo! Finance NASDAQ View Institutional Holdings for CELG - NASDAQ

Stock Charts

FinViz View CELG Stock Insight & Charts - StockCharts View CELG Investment Charts -
BarChart View CELG Stock Overview & Charts - BarChart Trading View View CELG User Generated Charts - Trading View

Latest Financial News for CELG

Incyte (INCY) Q4 2017 Earnings Conference Call Transcript
Posted on Tuesday February 20, 2018

INCY earnings call for the period ending December 31, 2017.

Pharmaceutical Titan’s Senate Bid Will Test Voters’ Views on Drug Prices
Posted on Tuesday February 20, 2018

Bob Hugin’s Celgene legacy could be both a blessing and a burden in the New Jersey election.

Kymriah May Emerge as a Robust Treatment Option in DLBCL Indication
Posted on Monday February 19, 2018

Novartis: What Are the Major Growth Drivers for 2018? On October 31, 2017, Novartis (NVS) announced the submission of a supplemental biologics license application (or sBLA) to the FDA. The sBLA seeks approval for Kymriah as a treatment option for adult patients with relapsed/refractory diffuse large B-cell lymphoma (or r/r DLBCL).

Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US
Posted on Monday February 19, 2018

Novartis: What Are the Major Growth Drivers for 2018? On August 30, 2017, Novartis’ (NVS) CAR T-cell therapy, Kymriah, secured approval from the FDA as a treatment option for patients below 25 years of age who have B-cell precursor acute lymphoblastic leukemia (or ALL). This drug, which is developed by the company in collaboration with the University of Pennsylvania, is indicated only in cases when ALL is refractory or has relapsed a second time or more.

Is Celgene A Growth Or A Value Stock?
Seeking Alpha - Feb 17, 2018
Let's take a look at Celgene's mission and vision statement. Celgene states that its mission is to "seek to deliver truly innovative and life-changing drugs for our patients" while its vision is to "build a major global biopharmaceutical corporation ...

Celgene Corporation Elects John Weiland to Its Board of Directors
Business Wire (press release) - Feb 15, 2018
Mr. Weiland started his career at Baxter/American Hospital Supply Corporation in 1977. He rose through numerous managerial positions including Vice President and General Manager of the Scientific Products Biomedical Division, Vice President and General ...

Celgene's Otezla-Colitis Story; Implications For Other Biotechs
Seeking Alpha - Feb 16, 2018
CELG put out an optimistically-titled press release regarding a mid-stage clinical trial for its newest blockbuster, Otezla. My interpretation of the data is at variance with that of CELG.
Is there a Bearish outlook for Celgene Corporation (NASDAQ:CELG) this week? - Reurope

Celgene In 2018: A Look At The Long Thesis
Seeking Alpha - Feb 13, 2018
For a large cap pharmaceutical company, the stock is incredibly cheap. Celgene's stock trades at a discount compared to most of its peers.
Traders Secrets on Celgene Corporation (CELG), The Kroger Co. (KR) - StockNewsJournal

Enter a stock symbol to view the stock details.